<DOC>
	<DOCNO>NCT00035802</DOCNO>
	<brief_summary>The purpose study determine safety efficacy topiramate adolescent manic mixed episode Bipolar I Disorder .</brief_summary>
	<brief_title>A Study Evaluate Safety Effectiveness Topiramate Compared Placebo Treatment Patients With Bipolar I Disorder</brief_title>
	<detailed_description>This 4-week study evaluate safety effectiveness topiramate compare placebo treatment Bipolar I Disorder optional 6-month open-label ( OL ) extension qualify patient follow completion study . On Days 1-28 patient receive placebo topiramate 2x/day mouth except 1st last dos single even dose single morning dose , respectively . Study drug titrate 100-mg increment 400 mg/day patient maintain stable dose Day 28 . During OL extension phase , topiramate titrate 5 day 200 mg/day . After Day 7 , topiramate may taper 100 mg/day 600 mg/day , clinically indicate .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Mood Disorders</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Affective Disorders , Psychotic</mesh_term>
	<mesh_term>Topiramate</mesh_term>
	<criteria>DSMIV diagnosis Bipolar I Disorder ( confirm KiddieSchedule Affective Disorders SchizophreniaPresent Lifetime version [ KSADSP/L ] ) YMRS score great equal 20 General good health determine medical history , physical examination , laboratory evaluation Ability swallow tablet Patient 's parent guardian must fully capable monitoring patient 's disease process compliance treatment Parent ( ) legal guardian ( ) must read sign informed consent form nature study fully explain assent must obtain patient DSMIV Axis I disorder diagnosis autistic disorder , schizophrenia , schizoaffective disorder , psychotic disorder otherwise specify ( NOS ) DSMIV diagnosis alcohol substance dependence , exception nicotine caffeine dependence , within 3 month prior baseline . Acute intermittent substance abuse prior screen exclusionary , depend upon clinical judgment investigator Chronic antidepressant treatment within 4 week randomization ( 5 week fluoxetine ) , use psychostimulants 7 day prior baseline , use psychotropic medication within 3 day 5 halflives , whichever less , prior baseline , requirement treatment psychotropic drug ongoing basis Weight le 33 kg current past history anorexia nervosa Serious unstable medical neurological condition</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Bipolar</keyword>
	<keyword>Mania</keyword>
	<keyword>Pediatric</keyword>
	<keyword>Children</keyword>
	<keyword>Adolescent</keyword>
	<keyword>Topiramate</keyword>
	<keyword>Anticonvulsants</keyword>
	<keyword>Central Nervous System Agents</keyword>
	<keyword>Protective Agents</keyword>
	<keyword>Neuroprotectiive Agents</keyword>
</DOC>